来源：睿智医药 而高莹莹被聘任为该公司董事会秘书才仅仅11天。 此前，12月1日盘后，睿智医药发布公告称，董事会秘书许剑提交书面辞职报告，称因工作调整原因申请提前卸任。同时，经公司董事长WOO SWEELIAN提名，董事会同意聘任高莹莹女士担任公司董事会秘书。 对于高莹莹的快速上任又离任，睿智医药在公告中并未透露更多信息。就此，南都·湾财社记者尝试致函询问情况，截至发稿尚未收到回复。 来源：睿智医药 根据公开资料，身为"90后"的高莹莹曾有8年的地方电视台主持人经验，此后方跨界至企业任职。 根据官网，睿智医药是一家全球领先的生物药、化学药一站式医药研发及生产服务提供商，致力于为全球制药企业、生物技术公司及科研院校提供 从早期发现到规模化生产的全生命周期一体化解决方案。然而，纵观高莹莹的履历，其中并无医药领域任职经验，也没有资本市场相关的任职经 验，因此部分股民对高莹莹的此番任职表示质疑。 不过，根据睿智医药12月1日的公告，高莹莹已取得深圳证券交易所颁发的《上市公司董事会秘书培训证明》，具备任职所需的工作经验和专业知 识，其任职资格符合《公司法》《深圳证券交易所上市公司自律监管指引第2号——创业板上市公司规范 ...

Core Insights - Beijing Zheyuan Technology Co., Ltd. announced the completion of A1 round financing amounting to 1 billion yuan [1] - The financing was led by Guokai Investment, with participation from Zeyuan Fund and Ruizhi Pharmaceutical [1] - The funds will be primarily used for advancing the core drug pipeline, global patent layout for high-value innovative IP, and upgrading the computational medicine platform [1] Company Developments - Zheyuan Technology is accelerating the development of multiple drug pipelines targeting complex diseases [1] - The company is focusing on self-developed drug pipelines for diseases such as pancreatic cancer, central nervous system tumors, chordoma, and liver cancer [1]

Core Viewpoint - The rapid resignation of Gao Yingying as the board secretary of Ruizhi Pharmaceutical raises questions about the company's management stability and the qualifications of its leadership [1][3][5]. Group 1: Management Changes - Gao Yingying applied for resignation from her position as board secretary just 11 days after her appointment, which was effective immediately upon delivery to the board [1][3]. - Her predecessor, Xu Jian, resigned on December 1, citing work adjustment as the reason for his early departure [3]. - The company has not provided further details regarding the reasons for Gao's quick departure, and inquiries from media have gone unanswered [5]. Group 2: Background of Gao Yingying - Gao Yingying, born in 1994, has a background as a television host with 8 years of experience before transitioning to corporate roles [6][8]. - She has held positions in various broadcasting companies and recently served as a promotion director at Zhongshan Anxin New Retail Company before joining Ruizhi Pharmaceutical [8]. - Despite her lack of experience in the pharmaceutical industry and capital markets, she has obtained the necessary qualifications to serve as board secretary, including a training certificate from the Shenzhen Stock Exchange [8]. Group 3: Compensation - The previous board secretary, Xu Jian, had a total pre-tax remuneration of 1.508 million yuan for 2024, with previous years' salaries being 1.67 million yuan in 2022 and 1.4443 million yuan in 2023 [9].

证券日报网讯12月15日，睿智医药（300149）在互动平台回答投资者提问时表示，截至2025年12月10日 公司的股东人数为39313户。 ...

智通财经记者 | 李科文 智通财经编辑 | 谢欣 12月12日晚间，睿智医药公告，公司董事会秘书高莹莹因工作职务调整，申请辞去董事会秘书职务，辞职报告自送达董事会之 日起生效。 值得注意的是，自就任睿智医药董事会秘书至辞职，高莹莹任职时间仅为11天。高莹莹此前并无上市公司董秘从业经历，职业 背景主要来自地方广播电视系统。 据履历信息，2016年7月至2020年3月，高莹莹在阳江广播电视台任策划、主持人、编导、编辑；2020年3月至2022年9月，在中 山广播电视台担任主持人、栏目策划及编导。其间，她曾与双胞胎姐姐高晶晶共同主持《晶莹睇透》《晶莹宝贝》《文学悦 听》《水上冲关》等节目。 12月15日，智通财经致电睿智医药董秘办，询问高莹莹离任是否与近期网络舆情有关。睿智医药投资者关系相关工作人员向智 通财经回应称，相关变动原因以公告披露内容为准。 睿智医药是国内较早成立的合同研究组织（CRO）公司。其前身睿智化学成立于2003年，在行业起步阶段，一度与如今的A股 医药合同研发生产组织（CDMO）龙头药明康德平齐。 胡瑞连曾是睿智化学的财务投资者。2017年5月，胡瑞连控制的Mega Star受让睿智化学23.5 ...

Core Viewpoint - Recently, Ruizhi Pharmaceutical (SZ300149) announced the resignation of its Secretary of the Board, Gao Yingying, due to job adjustments, which raises questions about management stability and continuity within the company [1][3]. Group 1: Management Changes - Gao Yingying, born in 1994, submitted her resignation just 11 days after taking office as Secretary of the Board, which is a notably short tenure [3]. - Gao was originally appointed to serve until the end of the sixth Board term and did not hold any shares in the company at the time of her resignation [3]. - The company has appointed the Chairman and CEO, Woosweelian, to temporarily assume the duties of the Secretary of the Board while a new appointment is made [3]. Group 2: Background of Gao Yingying - Gao Yingying holds a bachelor's degree and is currently pursuing a Master's in Business Administration at Shanghai Normal University [3]. - Prior to joining Ruizhi Pharmaceutical, she worked in various roles at local broadcasting stations from 2016 to 2022, including planning, hosting, directing, and editing [3]. - In November 2022, she transitioned to Zhongshan Anxin New Retail Co., Ltd. as Promotion Director before officially becoming the Secretary of the Board at Ruizhi Pharmaceutical in December 2025 [3]. Group 3: Company Overview - Ruizhi Pharmaceutical is a provider of integrated research and production services for biopharmaceuticals and chemical drugs, aiming to offer comprehensive lifecycle solutions from early discovery to large-scale production for global pharmaceutical companies, biotechnology firms, and research institutions [3].

Group 1 - The company announced the resignation of its board secretary, Gao Yingying, who had held the position for less than two weeks after being appointed on December 1, 2025 [1][2] - Gao Yingying was noted to have the necessary qualifications and experience for the role, having obtained the required training certification from the Shenzhen Stock Exchange [2] - The company has appointed its chairman and CEO, Woo Swee Lian, to act as the board secretary until a new appointment is made [3] Group 2 - Gao Yingying's previous experience includes roles in broadcasting and as a promotion director at a retail company before joining the firm [3] - The company has experienced significant fluctuations in its financial performance, with net profits of -1.55 billion, 4.02 billion, 3.63 billion, -9.17 billion, and -2.26 billion from 2020 to 2024, totaling over 1 billion in losses [3] - In the first three quarters of 2025, the company reported revenue of 8.17 billion, a year-on-year increase of 13.68%, and a net profit of 709.13 million, up 111.5% [3] Group 3 - As of December 12, 2025, the company's stock price was 9.82 CNY per share, with a total market capitalization of 4.89 billion [4][5]

来源：小王谈财经 来源：小王谈财经 ...

每经头条（nbdtoutiao）——实施城乡居民增收计划、降准降息等工具灵活高效运用、增加普通高中学 位……深度解读中央经济工作会议 （记者 曾健辉） 截至发稿，睿智医药市值为49亿元。 每经AI快讯，睿智医药（SZ 300149，收盘价：9.82元）12月12日晚间发布公告称，睿智医药科技股份 有限公司董事会秘书高莹莹女士因工作职务调整，申请辞去公司董事会秘书职务。 2025年1至6月份，睿智医药的营业收入构成为：医药研发服务及生产外包占比99.06%，益生元系列占 比0.52%，租金收入占比0.35%，其他行业占比0.07%。 ...

证券代码：300149 证券简称：睿智医药 公告编号：2025-80 睿智医药科技股份有限公司 关于高级管理人员辞职的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 电子邮箱：ir@chempartner.com 联系地址：广州市越秀区东风中路 268 号交易广场 28 楼 特此公告。 睿智医药科技股份有限公司（以下简称"公司"）董事会秘书高莹莹女士因工 作职务调整，申请辞去公司董事会秘书职务，辞职报告自送达董事会之日起生效。 高莹莹女士原定任期至公司第六届董事会届满为止。截至本公告披露日，高 莹莹女士未持有公司股份，亦不存在应当履行而未履行的承诺事项。 为保证董事会工作的正常进行，根据《公司法》《深圳证券交易所上市公司自 律监管指引第 2 号——创业板上市公司规范运作》《公司章程》等有关规定，公司 在聘任新的董事会秘书之前，公司董事会指定公司董事长、首席执行官（CEO） WOO SWEE LIAN 先生代行董事会秘书职责。公司将按照相关规定，尽快完成董 事会秘书的选聘工作。WOO SWEE LIAN 先生代行董事会秘书职责期间的联系方 式如下： 电话： ...